Sienna L. Mitman, Danielle A. Mzyk, Blanca E. Camacho, R. McAlister Council-Troche, Jennifer Davis, Derek M. Foster, Jennifer Halleran
{"title":"非那吡啶在梗阻性尿石症山羊体内的药代动力学","authors":"Sienna L. Mitman, Danielle A. Mzyk, Blanca E. Camacho, R. McAlister Council-Troche, Jennifer Davis, Derek M. Foster, Jennifer Halleran","doi":"10.1111/jvim.70167","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Phenazopyridine is used for ancillary pain management in the treatment of goats with obstructive urolithiasis. However, there are no published studies on the pharmacokinetics, safety, or efficacy of phenazopyridine in goats.</p>\n </section>\n \n <section>\n \n <h3> Hypothesis/Objectives</h3>\n \n <p>Determine the pharmacokinetic parameters of phenazopyridine after oral administration in goats with obstructive urolithiasis after tube cystostomy surgery.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Six male goats, ages 3 months to 4 years.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Prospective, observational study. Goats presenting to a veterinary institution diagnosed with obstructive urolithiasis underwent a tube cystostomy surgery. After surgery, phenazopyridine (4 mg/kg PO q12h) was administered. Plasma and urine samples were collected at predetermined intervals, and the concentration of phenazopyridine and clinically relevant metabolites was determined using ultra high-performance liquid chromatography with mass spectrometry. The pharmacokinetic parameters were determined using non-compartmental analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The harmonic mean terminal elimination plasma half-life (<i>T</i><sub>1/2</sub>), geometric mean maximum plasma concentration (<i>C</i><sub>max</sub>), and area under the curve (AUC) were 0.5 h (0.22–1.57 h), 263.4 ng/mL (137.35–1047.88 ng/mL), and 0.69 h*ng/mL (0.10–2.99 h*ng/mL), respectively for phenazopyridine. The concentration of phenazopyridine in urine samples was below the limit of assay detection (1.5 ng/mL) in all but one sample.</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Clinical Importance</h3>\n \n <p>Phenazopyridine was rapidly eliminated from plasma and did not concentrate at detectable levels in the urine after oral administration.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"39 4","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.70167","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis\",\"authors\":\"Sienna L. Mitman, Danielle A. Mzyk, Blanca E. Camacho, R. McAlister Council-Troche, Jennifer Davis, Derek M. Foster, Jennifer Halleran\",\"doi\":\"10.1111/jvim.70167\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Phenazopyridine is used for ancillary pain management in the treatment of goats with obstructive urolithiasis. However, there are no published studies on the pharmacokinetics, safety, or efficacy of phenazopyridine in goats.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Hypothesis/Objectives</h3>\\n \\n <p>Determine the pharmacokinetic parameters of phenazopyridine after oral administration in goats with obstructive urolithiasis after tube cystostomy surgery.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Animals</h3>\\n \\n <p>Six male goats, ages 3 months to 4 years.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Prospective, observational study. Goats presenting to a veterinary institution diagnosed with obstructive urolithiasis underwent a tube cystostomy surgery. After surgery, phenazopyridine (4 mg/kg PO q12h) was administered. Plasma and urine samples were collected at predetermined intervals, and the concentration of phenazopyridine and clinically relevant metabolites was determined using ultra high-performance liquid chromatography with mass spectrometry. The pharmacokinetic parameters were determined using non-compartmental analysis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The harmonic mean terminal elimination plasma half-life (<i>T</i><sub>1/2</sub>), geometric mean maximum plasma concentration (<i>C</i><sub>max</sub>), and area under the curve (AUC) were 0.5 h (0.22–1.57 h), 263.4 ng/mL (137.35–1047.88 ng/mL), and 0.69 h*ng/mL (0.10–2.99 h*ng/mL), respectively for phenazopyridine. The concentration of phenazopyridine in urine samples was below the limit of assay detection (1.5 ng/mL) in all but one sample.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions and Clinical Importance</h3>\\n \\n <p>Phenazopyridine was rapidly eliminated from plasma and did not concentrate at detectable levels in the urine after oral administration.</p>\\n </section>\\n </div>\",\"PeriodicalId\":49958,\"journal\":{\"name\":\"Journal of Veterinary Internal Medicine\",\"volume\":\"39 4\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-06-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.70167\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Internal Medicine\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvim.70167\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.70167","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景：非那吡啶用于治疗山羊梗阻性尿石症的辅助疼痛管理。然而，目前还没有发表关于非那吡啶在山羊体内的药代动力学、安全性或有效性的研究。假设/目的探讨非那吡啶在梗阻性尿石症山羊膀胱造瘘术后口服的药动学参数。动物6只公山羊，年龄3个月至4岁。方法前瞻性观察性研究。被诊断为梗阻性尿石症的山羊到兽医机构接受了管式膀胱造口手术。术后给予非那唑吡啶（4 mg/kg PO q12h）。按预定时间间隔采集血浆和尿液样本，采用超高效液相色谱-质谱法测定非那唑吡啶及临床相关代谢物的浓度。采用非区室分析确定药代动力学参数。结果非那唑吡啶的调和平均终端消除血浆半衰期（T1/2）为0.5 h (0.22 ~ 1.57 h)，几何平均最大血浆浓度（Cmax）为263.4 ng/mL (137.35 ~ 1047.88 ng/mL)，曲线下面积（AUC）为0.69 h*ng/mL （0.10 ~ 2.99 h*ng/mL）。除1份尿样外，其余尿样中非那唑吡啶浓度均低于测定检出限（1.5 ng/mL）。结论及临床意义口服给药后，非那吡啶能迅速从血浆中消失，且在尿液中未达到可检测的浓度。
Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis
Background
Phenazopyridine is used for ancillary pain management in the treatment of goats with obstructive urolithiasis. However, there are no published studies on the pharmacokinetics, safety, or efficacy of phenazopyridine in goats.
Hypothesis/Objectives
Determine the pharmacokinetic parameters of phenazopyridine after oral administration in goats with obstructive urolithiasis after tube cystostomy surgery.
Animals
Six male goats, ages 3 months to 4 years.
Methods
Prospective, observational study. Goats presenting to a veterinary institution diagnosed with obstructive urolithiasis underwent a tube cystostomy surgery. After surgery, phenazopyridine (4 mg/kg PO q12h) was administered. Plasma and urine samples were collected at predetermined intervals, and the concentration of phenazopyridine and clinically relevant metabolites was determined using ultra high-performance liquid chromatography with mass spectrometry. The pharmacokinetic parameters were determined using non-compartmental analysis.
Results
The harmonic mean terminal elimination plasma half-life (T1/2), geometric mean maximum plasma concentration (Cmax), and area under the curve (AUC) were 0.5 h (0.22–1.57 h), 263.4 ng/mL (137.35–1047.88 ng/mL), and 0.69 h*ng/mL (0.10–2.99 h*ng/mL), respectively for phenazopyridine. The concentration of phenazopyridine in urine samples was below the limit of assay detection (1.5 ng/mL) in all but one sample.
Conclusions and Clinical Importance
Phenazopyridine was rapidly eliminated from plasma and did not concentrate at detectable levels in the urine after oral administration.
期刊介绍：
The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
